Scancell Holdings plc

Equities

SCLP

GB00B63D3314

Biotechnology & Medical Research

Market Closed - London S.E. 12:35:29 2024-03-28 pm EDT 5-day change 1st Jan Change
10.25 GBX 0.00% Intraday chart for Scancell Holdings plc -2.38% -2.38%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Scancell doses first patient in melanoma-focused trials AN
Seneca Growth Capital announces tepid 2023 results AN
Scancell Holdings plc Appoints Sath Nirmalananthan to the Board CI
Alliance Pharma appoints chair; FireAngel sales down AN
Scancell's Chief Development Officer to Step Down MT
Scancell Holdings plc Directorate and Executive Changes Changes CI
Scancell interim loss narrows amid finance gain on derivative AN
Scancell Holdings plc Reports Earnings Results for the Half Year Ended October 31, 2023 CI
Scancell approved by MHRA to add new cohort to Scope trial AN
Scancell Holdings plc Announces Update on SCOPE Trial CI
Scancell Raises GBP1.2 Million Via Open Offer MT
Scancell raises GBP12 million in total from fundraise AN
Scancell Raises GBP11 Million via Share Issue MT
Scancell raises GBP10.7 million in upsized share sale AN
EARNINGS AND TRADING: Dispensa and SkinBioTherapeutics losses widen AN
Scancell’s Skin Cancer Vaccine Trial Advances to Second Stage; Shares Up MT
Scancell trial progresses; OptiBiotix inks new deal AN
Scancell shares up as presents "trailblazing" trial data AN
EARNINGS: Frontier IP chair to step down; "busy" Rosslyn narrows loss AN
Earnings Flash (SCLP.L) SCANCELL HOLDINGS Reports FY23 Revenue GBP5.3M MT
Scancell Holdings plc Reports Earnings Results for the Full Year Ended April 30, 2023 CI
Scancell says needs more time to publish annual results AN
Pharmajet Partner, Scancell, Announces Positive Data from the First Stage of Its Phase 2 Trial of Advanced Melanoma Dna Vaccine Delivered Needle-Free CI
Oxford Technology 2 VCT asset value hurt by AIM share falls AN
Scancell celebrates "positive" clinical trial data for cancer vaccine AN
Chart Scancell Holdings plc
More charts
Scancell Holdings plc is a United Kingdom-based clinical-stage biopharmaceutical company. The Company is a developer of immunotherapies for the treatment of cancer and infectious diseases. The Company is building a pipeline of products by utilizing its four technology platforms: Moditope and ImmunoBody for vaccines and GlyMab and AvidiMab for antibodies. Its products pipeline includes Modi-1, Modi-2, SCIB1 & iSCIB1+, SCIB2 & iSCIB2, SCOV1 and SCOV2 (COVIDITY), as well as Anti-glycan antibodies. Modi-1, which targets citrullinated cancer antigens, is the first therapeutic vaccine candidate to emerge from Scancell's Moditope platform. Modi-2, which targets homocitrullinated cancer antigens, is the second therapeutic vaccine candidate from the Company's Moditope platform. SCIB1 is the lead product from its ImmunoBody immunotherapy platform, which identifies, attacks and destroys tumors. The COVIDITY program, focuses on the Company's COVID-19 vaccine candidates, SCOV1 and SCOV2.
Calendar
2024-05-14 - CIMT Meeting
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
3
Last Close Price
0.1025 GBP
Average target price
0.2473 GBP
Spread / Average Target
+141.30%
Consensus

Annual profits - Rate of surprise

  1. Stock
  2. Equities
  3. Stock Scancell Holdings plc - London S.E.
  4. News Scancell Holdings plc
  5. Scancell : to Start Trial for Novel Bivalent COVID-19 Vaccine in UK, South Africa; Shares Soar 11%